ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 25.04

+0.9%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (403)	3/29/2007 2:11:41 PM
From: Ian@SI	Read Replies (1) of 588

Another entrant??? Or are 5-HT1A and 5-HT2A completely non-overlapping? .EPIX Pharmaceuticals (EPIX) announces that it has initiated a Phase 2b clinical trial to evaluate the efficacy of PRX-00023, a selective 5-HT1A partial agonist, in patients with a primary diagnosis of major depressive disorder who also have concurrent anxiety. Data from this trial are expected in 1H08.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next